adozelesin and Genital-Neoplasms--Female

adozelesin has been researched along with Genital-Neoplasms--Female* in 2 studies

Other Studies

2 other study(ies) available for adozelesin and Genital-Neoplasms--Female

ArticleYear
In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:1

    Adozelesin is a derivative of an extremely cytotoxic compound, CC1065. This entirely new class of drug binds preferentially to DNA and facilitates alkylation reaction. In the present study, we used the adenosine triphosphate (ATP) chemosensitivity assay to compare the cytotoxic potency of Adozelesin with that of common chemotherapeutic agents in ten gynecologic-cancer cell lines. Flow cytometry was also used to study its effects on cell-cycle kinetics. The mean drug concentrations required to produce a 50% reduction in ATP levels as compared with controls [IC50] were: Adriamycin, 0.17 +/- 0.06 microM; 4OH-Cytoxan, 18 +/- 3 microM; cisplatin, 17 +/- 7 microM; 5-fluorouracil, 183 +/- 116 microM; and Adozelesin, 11.0 +/- 5.4 pM. Thus, Adozelesin was 10(4) - 10(7) times more potent than Adriamycin, cisplatin, 5-fluorouracil, and Cytoxan. Cell kinetics studies revealed significant S and G2 blocks such as those previously reported for other alkylating agents.

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzofurans; Cell Cycle; Cyclohexanecarboxylic Acids; Cyclohexenes; Drug Screening Assays, Antitumor; Duocarmycins; Female; Genital Neoplasms, Female; Humans; Indoles; Kinetics; Tumor Cells, Cultured; Uterine Neoplasms

1992
Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:7

    Adolezesin is an analog of CC-1065. These compounds are among the most potent alkylating agents known to date. Currently Adolezesin is undergoing phase I clinical trials at several cancer centers in the USA. While the cytotoxic effects of Adolezesin have been addressed elsewhere, its effects on cell-cycle kinetics have not been reported. Flow cytometry was performed on five human gynecological cancer cell lines: AN3, AE7, BG1, HEC1A, and SKUT1B. Exposure to Adolezesin (U73975, Upjohn Co.) was done at near confluency at 0, 0.1, 0.2, 0.5, 1 and 5x, with x = 10 pg/ml as reference concentration, for 90 min. Cell samples were taken by trypsinization at 0, 24, 48, 72, 96, and 168 h for flow cytometry. The ATP chemosensitivity assays were performed on the above cell lines to establish dose/response curves. Flow-cytometric analyses revealed that there was a spectrum of cell-cycle perturbations, which included biphasic S and G2 blocks, reverse dose-dependent G2 blocks, and a sequential relationship of S and G2 blocks. This study demonstrated that the cell kinetic response to Adolezesin depended on several variables such as cell lines, drug sensitivity, concentrations, and sampling time. Because of this multivariable dependence and the lack of correlation with cytotoxicity, it would be difficult to use cell kinetic pertubations to predict chemotherapeutic response.

    Topics: Adenosine Triphosphate; Alkylating Agents; Antineoplastic Agents; Benzofurans; Cell Cycle; Cyclohexanecarboxylic Acids; Cyclohexenes; Dose-Response Relationship, Drug; Duocarmycins; Female; Flow Cytometry; Genital Neoplasms, Female; Humans; Indoles; Tumor Cells, Cultured

1992